摘要
目的探讨外科治疗Ⅲ期食管癌患者的生存状况。方法回顾性分析96例食管癌患者的临床资料,根据随访结果,统计Ⅲ期食管癌患者的1、3及5年生存率,并根据患者5年生存状况将患者分为生存组和死亡组,比较两组患者的性别、年龄、手术方式、肿瘤直径、病理类型、是否合并慢性疾病、病理残端切除方式、是否淋巴结转移、是否合并脉管瘤栓、T分期、N分期、TMN分期及术后辅助治疗方式,确定手术治疗食管癌患者5年生存率的相关影响因素和独立影响因素,并进一步确定不同术后辅助治疗方式患者的5年生存率。结果 96例患者1年生存率74.0%(71/96),3年生存率33.3%(32/96),5年生存率为26.0%(25/96),患者平均生存时间为24.1个月;确定手术方式、肿瘤部位、N分期、TMN分期及术后辅助治疗方式为外科治疗Ⅲ期食管癌患者的5年生存率的相关影响因素;确定TMN分期、术后辅助治疗方式为外科治疗Ⅲ期食管癌患者5年生存率的独立影响因素;Ⅲa患者术后接受不同辅助治疗5年生存率的差异具有统计学意义,Ⅲb和Ⅲc患者术后接受不同辅助治疗5年生存率的差异无统计学意义。结论 TMN分期、术后辅助治疗方式为外科治疗Ⅲ期食管癌患者5年生存率的独立影响因素。对于临床分期越晚的患者,5年生存率越低,术后放化疗可以有效的提升患者的生存状况。
Objective To explore the survival status of surgical treatment of stage Ⅲ esophageal cancer. Methods The clinical data of 96 patients with esophageal cancer were analyzed retrospectively. According to the follow-up results, the 1 year, 3-year and 5-year survival rate of esophageal cancer were collected. The patients were divided into survival group and death group according to their living condition for 5 years. The sex ratio, age distribution, operation style, tumor diameter, pathologic type, chronic disease and pathologic stump resection were compared between the two groups. T staging, N staging, TMN staging and postoperative adjuvant therapy were used to determine the factors influencing 5-year survival rate of patients with gallbladder carcinoma after operation. The factors influencied the 5- year survival rate of gallbladder carcinoma were determined. Results The 1-year survival rate was 74.0%（71/96）, 3-year survival rate was 33.3% （32/96）, 5-year survival rate was 26.0% （25/96）, and the mean survival time was 24.1 months. The surgical approach, the tumor site, N stage, TMN staging and adjuvant treatment were relevant factors in the surgical treatment of 5-year survival of patients with esophageal cancer Ⅲ. TMN stage and postoperative adjuvant therapy were the independent influencing factors of 5-year survival rate in patients with stage Ⅲ esophageal cancer. There were statistically difference in the 5-year survival rate of patients with stage Ⅲa after receiving different adjuvant therapy. There was no significant difference in the survival rate of patients with Ⅲb and Ⅲc after 5 years of different adjuvant therapy. Conclusions TMN staging and postoperative adjuvant therapy are the independent prognostic factors for the 5-year survival rate of patients with stage Ⅲ esophageal carcinoma. For the late clinical stage of patients, 5-year survival rate is lower, postoperative radiotherapy and chemotherapy can effectively improve the survival of patients.
出处
《中国现代医学杂志》
CAS
北大核心
2017年第15期87-91,共5页
China Journal of Modern Medicine
基金
内蒙古卫计委医疗卫生科研计划项目(No:201301057)
关键词
外科治疗
Ⅲ期
食管癌
生存状况
surgical treatment
stage Ⅲ
esophageal cancer
survival status
